This article is more than 5 years old. Information may no longer be current.

NovaBay reports third-quarter net loss of $5.2 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaBay Pharmaceuticals reported a net loss of $5.2 million, or $0.07 per share, in the third quarter compared with a net loss of $4.2 million, or $0.08 per share, in the same period of 2014, according to a press release.

The increase was attributed to higher spending on sales and marketing for Avenova and partially offset by less spending on research and development.

Net sales were reported at $1.2 million in the third quarter compared with $152,000 in the same period of 2014.

Quarterly product revenue was reported at $1.1 million compared with $90,000 in the same period of 2014.